SJ
Steven J. Romano, M.D.
Former Executive Vice President and Chief Scientific Officer
Mallinckrodt PharmaceuticalsMallinckrodt Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Terlipressin (TERLIVAZ®) | Hepatorenal Syndrome Type 1 (HRS-1) | Approved |
| Stannsoporfin (INH-001) | Prevention of severe hyperbilirubinemia in newborns | Phase 3 |
| StrataGraft | Thermal Burns | Approved |
| H.P. Acthar® Gel | Multiple autoimmune/inflammatory conditions | Approved |
Leadership Team at Mallinckrodt Pharmaceuticals
S(
Sigurdur (Siggi) Olafsson
Former President and CEO
BM
Bryan M. Reasons
Former Executive Vice President and CFO